00:20 , Aug 23, 2019 |  BC Innovations  |  Distillery Therapeutics

Hydrogels with montmorillonite could repair bone defects

DISEASE CATEGORY: Musculoskeletal INDICATION: Bone repair Delivering the clay mineral montmorillonite, which could serve as a scaffold for cells, as part of a nanocomposite hydrogel could treat bone defects. The nanocomposite hydrogels are synthesized by...
23:14 , Aug 22, 2019 |  BC Innovations  |  Translation in Brief

A telltale mouse to guide AAV design for gene editing

A study from Spark co-founder Beverly Davidson suggests AAV vectors can reach more tissues than previously thought, opening up new opportunities and guidelines for AAV-mediated gene editing. In a Nature Communications paper , Davidson’s team...
02:02 , Aug 10, 2019 |  BioCentury  |  Product Development

Eat this, don’t eat that: CD47 companies’ first hurdle

The rush to drug CD47 shows no signs of abating, with five companies launching clinical programs for cancer this year and three moving forward on the back of encouraging Phase I data. The differentiator may...
00:05 , Aug 9, 2019 |  BC Innovations  |  Tools & Techniques

The next frontier for single-cell analysis

With an explosion in scalability, single-cell analysis has begun to invade every aspect of drug development, with early benefits showing themselves in precision targeting. The field’s next challenge is to integrate a wider array of...
23:30 , Aug 2, 2019 |  BC Extra  |  Financial News

Aug. 2 Financial Quick Takes: Rakuten Medical bags another $100M; plus CGeneTech, Zecen, Qyuns and more

Rakuten Medical raises another $100 million  Rakuten Medical Inc. (San Diego, Calif.) raised $100 million in a series C-1 round from existing investor Rakuten Inc. (Tokyo:4755), giving the Japanese internet giant a 22.6% stake. The...
23:10 , Aug 1, 2019 |  BC Innovations  |  Emerging Company Profile

NeoPhore: Driving neoantigen production via DNA mismatch repair

NeoPhore is turning cold tumors hot by inhibiting DNA mismatch repair to produce more of the neoantigens that trigger immune attack. Immuno-oncology companies are developing therapies based on neoantigens -- tumor-specific peptides that the immune...
22:45 , Jul 26, 2019 |  BC Extra  |  Clinical News

Patient preferences could influence mortality requirements in heart failure

Companies that were seeking more clarity on mortality requirements of heart failure therapies that provide symptomatic benefit didn't get it at a Friday workshop hosted by FDA. Instead, doctors and patients suggested that multiple factors...
23:45 , Jul 24, 2019 |  BC Extra  |  Company News

July 24 Company Quick Takes: Samsung's Humira biosimilar gets FDA approval; plus Intra-Cellular, Sage and more

FDA approves Samsung's Humira biosimilar  Samsung Bioepis Co. Ltd. (Incheon, South Korea) said FDA approved Hadlima adalimumab-bwwd, a biosimilar of autoimmune drug Humira from AbbVie Inc. (NYSE:ABBV). Samsung's partner Merck & Co. Inc. (NYSE:MRK) will...
22:46 , Jul 24, 2019 |  BC Extra  |  Financial News

New investors bring key connections to Freenome’s machine learning diagnostics

A host of first-time investors joined a $160 million series B round for machine learning-powered cancer diagnostics company Freenome, bringing a diverse set of connections as the company maps out its go-to-market strategy and goals...
22:17 , Jul 24, 2019 |  BC Innovations  |  Translation in Brief

Unraveling checkpoint responses in PD-L1-negative cancers

A new study from City of Hope offers a long-sought explanation for why some patients lacking PD-L1 expression on their tumors respond to antibodies against the target, and uncovers a way to boost NK cell...